Menopause and Weight Loss

New data points to menopause and GLP-1 receptor agonists (weight loss meds) both playing a role in metabolic function, weight management and other related conditions. Along with the hormonal changes with menopause (drop in estrogen) there is commonly a notable weight gain around abdomen along with reduced metabolic rate and in many increased  insulin resistance. This weight gain around abdomen and reduced metabolic rate are noted in men as they age with declining testosterone levels and growth hormone levels as well.  

GLP-1 receptors agonists (weight loss meds) were originally designed and used for type 2 diabetes.  They are FDA approved for use in weight management/obesity.  They promote weight loss because of their mechanism that increases insulin secretion in response to meals, delays gastric emptying promoting a feeling of fullness and suppresses appetite which leads to reduced caloric intake.  

For menopausal women using GLP-1 receptor agonist (weight loss meds) has been shown to promote weight loss linked to menopause and declining estrogen levels.  Menopause related insulin resistance can be counteracted by using GLP-1 therapy (weight loss meds) which also reduces risk of type 2 diabetes.There is also data showing that GLP-1 receptor agonists (weight loss meds)  show cardiovascular protective effects which is beneficial because after menopause cardiovascular risks increase in women. 

Mod Med is lead  by a board certified ObGyn, we feel that GLP-1s can be used with hormone replacement therapy (HRT). HRT addresses the menopausal symptoms like hot flashes and night sweats and slowing rate of bone loss.  But new data shows that combining HRT with GLP-1s might offer synergistic benefits for managing weight and metabolic health.  

-Tyler Handcock MD